{"nctId":"NCT00777920","briefTitle":"Study of Ambrisentan in Participants With Pulmonary Hypertension","startDateStruct":{"date":"2008-11-17","type":"ACTUAL"},"conditions":["Pulmonary Hypertension"],"count":140,"armGroups":[{"label":"Ambrisentan","type":"EXPERIMENTAL","interventionNames":["Drug: Ambrisentan"]}],"interventions":[{"name":"Ambrisentan","otherNames":["LetairisÂ®","Volibris"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Men and women with pulmonary hypertension who are discontinuing a clinical study of ambrisentan due to study closure by the sponsor. Eligible participants are those participating in countries where ambrisentan is not yet commercially available. Participants participating in countries where ambrisentan is commercially available may be eligible if they do not qualify for treatment per the current prescribing information of that country.\n\nKey Exclusion Criteria:\n\n* Participants who have discontinued an ambrisentan clinical study for any other reason than sponsor-initiated study closure are not eligible.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":80,"n":140},"commonTop":["Oedema peripheral","Upper respiratory tract infection","Dyspnoea","Headache","Palpitations"]}}}